🏥 Managed at our clinic: Our endocrinologists prescribe Forteo for patients with severe osteoporosis throughout Houston. Book a consultation →
Forteo (teriparatide) is a daily injectable medication for severe osteoporosis that works differently from most bone medications. Instead of slowing bone breakdown, Forteo actively builds new bone by stimulating osteoblasts — the cells that lay down new bone matrix. It is a synthetic fragment of parathyroid hormone (PTH 1-34), FDA-approved for postmenopausal women, men, and patients on long-term corticosteroids (glucocorticoid-induced osteoporosis).
Anabolic vs. Antiresorptive: Why It Matters
Fosamax, Reclast, Prolia, Raloxifene — these slow bone destruction. They preserve the bone you have but don't create new structure.
Forteo stimulates osteoblasts to actively build new bone. It creates new bone architecture — particularly important for patients with severely weakened bone structure.
What to Expect on Forteo
- Injection: Once daily, subcutaneous (under the skin) in the thigh or abdomen using a prefilled auto-injector pen
- Duration: Up to 2 years (24 months) — the lifetime maximum
- Storage: Keep refrigerated; discard pen after 28 days
- Tip: Inject at bedtime to minimize lightheadedness. Sit or lie down for a few minutes after the first several injections
Clinical Results
- Reduces new vertebral fractures by approximately 65%
- Reduces nonvertebral fractures by approximately 53%
- Spine BMD increases ~9–13% over 2 years
- Particularly effective for glucocorticoid-induced osteoporosis (steroid-related bone loss)
⚠️ After Forteo — Follow-On Therapy is Essential: When Forteo is stopped, bone density declines if no antiresorptive medication is started. Your endocrinologist will prescribe a follow-on medication (Prolia, Reclast, or bisphosphonate) as your Forteo course ends. This is a critical step in your treatment plan.
Who Is a Good Candidate for Forteo?
- Severe osteoporosis (T-score ≤ -3.0 or multiple fractures)
- Glucocorticoid-induced osteoporosis (long-term prednisone or steroids)
- Patients who have had fractures despite antiresorptive therapy
- Patients able and willing to do daily injections for 2 years
- Not for: Patients with Paget's disease, prior radiation to skeleton, unexplained elevated alkaline phosphatase, or hypercalcemia
Osteoporosis Medication Comparison
| Medication | Class | How Given | Frequency | Special Notes |
|---|---|---|---|---|
| Fosamax | Bisphosphonate | Pill | Weekly | Take fasting, stay upright 30 min |
| Actonel | Bisphosphonate | Pill | Weekly/Monthly | Take fasting, stay upright 30 min |
| Reclast | Bisphosphonate | IV infusion | Once yearly | No weekly pill compliance issues |
| Prolia | RANK-L inhibitor | Injection | Every 6 months | ⚠️ NEVER miss a dose — rebound fracture risk |
| Forteo | Anabolic (PTH) | Daily injection | Daily × 2 yrs | Builds new bone; requires follow-on therapy |
| Tymlos | Anabolic (PTHrP) | Daily injection | Daily × 2 yrs | Builds new bone; requires follow-on therapy |
| Evenity | Dual-action | Monthly injection | Monthly × 12 | Builds AND protects bone; caution w/ CV history |
| Raloxifene | SERM | Daily pill | Daily | Also reduces breast cancer risk |
Frequently Asked Questions About Forteo
What is Forteo and how does it work?
Forteo (teriparatide) is a daily injectable medication that builds bone by stimulating osteoblasts — the cells responsible for creating new bone. It is a synthetic form of PTH (parathyroid hormone) fragment (1-34). Unlike antiresorptive medications (Prolia, bisphosphonates) that slow bone breakdown, Forteo actively stimulates new bone formation — making it an 'anabolic' agent. It is FDA-approved for osteoporosis in postmenopausal women, men, and patients on long-term corticosteroids.
How long do you take Forteo?
Forteo is taken for a maximum of 2 years (24 months) over a lifetime. The FDA limits lifetime use to 2 years due to historical osteosarcoma risk observed in rat studies at very high doses (this has not been shown in humans, but the precaution is maintained). After completing Forteo, patients must transition to an antiresorptive medication (Prolia or bisphosphonate) to preserve the bone density gains.
How do you take Forteo?
Forteo is injected subcutaneously (under the skin) once daily, using a prefilled injection pen. The injection is given in the thigh or abdomen. The pen is refrigerated and discarded after 28 days of use. Many patients choose to inject at bedtime to sleep through any initial lightheadedness.
What are the side effects of Forteo?
Common side effects include nausea, dizziness, and leg cramps. Orthostatic hypotension (lightheadedness when standing up) can occur, especially with the first few injections — sitting or lying down for a few minutes after injection reduces this. Serum calcium may increase slightly, so your endocrinologist will monitor calcium and kidney function. A black box warning exists for osteosarcoma (bone cancer) based on rat studies at very high doses; this risk has not been demonstrated in human clinical use.
Who is a good candidate for Forteo?
Forteo is best suited for patients with severe osteoporosis, multiple fractures, or very high fracture risk who need more than antiresorptive therapy can provide. It's also used for glucocorticoid-induced osteoporosis (from long-term prednisone or similar medications) and for patients who have failed antiresorptive therapy. It requires daily injections, so patient commitment is important.
What happens after 2 years of Forteo?
After completing the 2-year Forteo course, transition to antiresorptive therapy (Prolia, Reclast, or oral bisphosphonates) is essential to preserve the bone density gained. Without a follow-on medication, bone density will decline — sometimes rapidly. Your endocrinologist will plan this transition as part of your overall treatment strategy.
Key Takeaways
- Forteo builds new bone rather than just slowing breakdown — uniquely important for severe osteoporosis
- Daily subcutaneous injection for up to 2 years (lifetime maximum)
- Reduces vertebral fractures by ~65% and nonvertebral fractures by ~53%
- Must transition to antiresorptive therapy (Prolia, Reclast) after completing the course
- Black box warning for osteosarcoma based on animal data — not demonstrated in human use